Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-related disease (IgG4-RD). Acquired as part of its $27.8 ...
The diagnosis of IgG4 cholangiopathy often relies on identifying a supporting combination of clinical, laboratory, radiologic, and histologic findings. Occasionally, assessing the clinical response to ...
WASHINGTON — The B-cell depleting agent inebilizumab (Uplizna) dramatically reduced the risk of flares and increased year-long remission of IgG4-related disease (RD), new research has found. The ...
In a recent study posted to bioRxiv* preprint server, researchers in Germany assessed the differences in antigen-specific immunoglobulin G (IgG) subtypes between post-COVID syndrome (PCS) patients and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback